Bristol-Myers Squibb Change in Accrued Liabilities increased by 93.3% to $1.70B in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 6.4%, from $1.82B to $1.70B.
An increase represents a source of cash through deferred payment, while a decrease represents a cash outflow as obligations are settled.
Reflects the change in obligations for expenses incurred but not yet invoiced or paid, such as employee compensation, ta...
Standard operating cash flow component found in almost all corporate financial statements.
cf_change_in_accrued_liabilities| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $215.00M | $908.00M | $0.00 | -$930.00M | $520.00M | $1.14B | -$910.00M | $492.00M | $1.53B | -$665.00M | $735.00M | $1.82B | -$627.00M | $881.00M | $1.70B |
| QoQ Change | — | +322.3% | -100.0% | — | +155.9% | +119.2% | -179.8% | +154.1% | +211.6% | -143.4% | +210.5% | +147.5% | -134.5% | +240.5% | +93.3% |
| YoY Change | — | — | — | — | +141.9% | +25.6% | +2.2% | -5.4% | +34.5% | +26.9% | +49.4% | +18.7% | +5.7% | +19.9% | -6.4% |
We use cookies for analytics. See our Privacy and Cookie Policy.